Kalvista Pharmaceuticals Inc Total Liabilities
Kalvista Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Kalvista Pharmaceuticals Inc (KALV) has total liabilities worth $322.93 Million USD as of October 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Kalvista Pharmaceuticals Inc to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Kalvista Pharmaceuticals Inc (2013–2025)
Total liabilities of Kalvista Pharmaceuticals Inc from 2013 to 2025. This chart illustrates how Kalvista Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data.
Kalvista Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Kalvista Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai Anoky Group
SHE:300067
|
China | CN¥1.03 Billion |
|
Africa Oil Corp
TO:AOI
|
Canada | CA$1.59 Billion |
|
Cheng Loong Corp
TW:1904
|
Taiwan | NT$42.55 Billion |
|
Arteris Inc
NASDAQ:AIP
|
USA | $129.66 Million |
|
Shen Ma Industry Co Ltd
SHG:600810
|
China | CN¥18.63 Billion |
|
Evolv Technologies Holdings Inc
NASDAQ:EVLV
|
USA | $183.16 Million |
|
Shanghai Baolong Automotive Corp
SHG:603197
|
China | CN¥8.21 Billion |
|
Hubei Jiuzhiyang Infrared System Co Ltd
SHE:300516
|
China | CN¥611.14 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down Kalvista Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Kalvista Pharmaceuticals Inc (KALV) total assets.
Liquidity & Leverage Metrics
Kalvista Pharmaceuticals Inc Total Liabilities Ratios Explained
Kalvista Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 19.00 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.95 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kalvista Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kalvista Pharmaceuticals Inc (2013–2025)
The table below shows the annual total liabilities of Kalvista Pharmaceuticals Inc from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-04-30 | $155.38 Million | +439.10% |
| 2024-04-30 | $28.82 Million | +29.96% |
| 2023-04-30 | $22.18 Million | +18.04% |
| 2022-04-30 | $18.79 Million | +26.77% |
| 2021-04-30 | $14.82 Million | +68.85% |
| 2020-04-30 | $8.78 Million | -58.97% |
| 2019-04-30 | $21.39 Million | -37.33% |
| 2018-04-30 | $34.14 Million | +1031.08% |
| 2017-04-30 | $3.02 Million | -7.11% |
| 2016-04-30 | $3.25 Million | -50.80% |
| 2016-03-31 | $6.60 Million | -11.72% |
| 2015-12-31 | $7.48 Million | -85.28% |
| 2015-04-30 | $50.83 Million | +351.02% |
| 2014-12-31 | $11.27 Million | -74.28% |
| 2014-04-30 | $43.81 Million | +19.01% |
| 2013-04-30 | $36.81 Million | -- |
About Kalvista Pharmaceuticals Inc
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which … Read more